Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07098039Not ApplicableNot Yet Recruiting

Cardio-Fit2: Impact of a Cardiac Rehabilitation Program in Patients With Cardiovascular Disease

Role: lead

NCT06211361Not ApplicableActive Not Recruiting

Cardiac Rehabilitation Program in Patients with Cardiovascular Disease

Role: collaborator

NCT06043206Completed

Bariatric Surgery in Patients With Schizophrenia

Role: collaborator

NCT02333292Completed

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

Role: collaborator

NCT00397709Phase 4Terminated

Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection

Role: lead

All 5 trials loaded